Drug Trial Radar · NCT04886154
A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,440
Actual
Start
Jun 14, 2021
Primary completion
Feb 2, 2024
Study completion Feb 2, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety, effectiveness, and immune response of the meningococcal combined ABCWY vaccine (GSK4023393A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups. The first time-in-human (FTIH), Phase I part of this study was conducted in healthy adults in a dose-escalating fashion with 2 formulations of the investigational MenABCWY-2Gen vaccine and served as a safety lead-in to the Phase II study. The Phase II part of the study was conducted in 2 parts: The 'formulation and schedule-finding' part followed in healthy adolescents and young adults and was designed to select the vaccine formulation and the schedule to be tested in Phase III. The 'blood sourcing' part was conducted in healthy adults in order to collect sufficient serum samples for the development of assays to be used in the MenABCWY-2Gen vaccine clinical development program.
Conditions
- Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccineCombination product
MenABCWY-2Gen low dose vaccine is administered intramuscularly as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose\_06 Group and ABCWY low dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose\_01 Group, ABCWY low doseS\_02 Group and ABCWY low doseS\_06 Group in study Phase II (Sourcing).
MenABCWY-2Gen high dose vaccineCombination product
MenABCWY-2Gen high dose vaccine is administered intramuscularly 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose\_06 Group and ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose\_01 Group, ABCWY high doseS\_02 Group and ABCWY high doseS\_06 Group in study Phase II (Sourcing).
PlaceboCombination product
Placebo is administered intramuscularly as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose\_06 Group, ABCWY low dose\_02 Group, ABCWY high dose\_06 Group, ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding).
MenB vaccineCombination product
MenB vaccine is administered intramuscularly as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
MenACWY vaccineBiological
MenACWY vaccine is administered intramuscularly as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Solicited Administration Site Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Solicited Administration Site Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
- Number of Participants With Solicited Systemic Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Solicited Systemic Events in Study Phase I (Safety Lead-in)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
- Number of Participants With Any Unsolicited Adverse Events (AEs), Including All Serious Adverse Events (SAEs), AEs Leading to Withdrawal and AEs of Special Interest (AESIs) in Study Phase I (Safety Lead-in)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Any Unsolicited AEs, Including All SAEs, AEs Leading to Withdrawal and AESIs in Study Phase I (Safety Lead-in)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 31
- Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase I (Safety Lead-in)Time frame: Throughout the Phase 1 study period (Day 1 through Day 211)
- Number of Participants With Change From Baseline in Haematological and Biochemical Laboratory Values, in Study Phase I (Safety Lead-in)Time frame: At Day 8 (7 days after the first vaccination)
- Number of Participants With Clinically Significant Haematological and Biochemical Laboratory Values, in Study Phase I (Safety Lead-in)Time frame: At Day 8 (7 days after the first vaccination)
- Percentage of Blood Samples With Bactericidal Serum Activity Using Enc-hSBA Against a Panel of 110 Randomly Selected Endemic US N. Meningitidis Serogroup B Invasive Disease Strains at Study Phase II (Formulation and Schedule-finding)Time frame: At Day 211 (1 month after the last vaccination)
- Number of Participants With a 4-fold Rise in hSBA Titers Against Serogroups A, C, W and Y in Study Phase II (Formulation and Schedule-finding)Time frame: At Day 211 for ABCWY groups (1 month after the last MenABCWY-2Gen vaccination) and at Day 31 for Control group (1 month after the last MenACWY vaccination)
- Number of Participants With Solicited Administration Site Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Solicited Administration Site Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 121
- Number of Participants With Solicited Administration Site Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
- Number of Participants With Solicited Systemic Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Solicited Systemic Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 121
- Number of Participants With Solicited Systemic Events in Study Phase II (Formulation and Schedule-finding)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
- Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Formulation and Schedule-finding)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Formulation and Schedule-finding)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 121
- Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Formulation and Schedule-finding)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 181
- Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Formulation and Schedule-Finding)Time frame: Throughout the Phase II FSF study period (Day 1 through Day 541)
- Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
- Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 61
- Number of Participants With Solicited Administration Site Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
- Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 31
- Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 61
- Number of Participants With Solicited Systemic Events in Study Phase II (Sourcing)Time frame: During the 7 days (including the day of vaccination) following vaccination at Day 181
- Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 1
- Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 31
- Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 61
- Number of Participants With Any Unsolicited AEs (Including All SAEs, AEs Leading to Withdrawal, and AESIs) in Study Phase II (Sourcing)Time frame: During the 30 days (including the day of vaccination) following vaccination at Day 181
- Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Sourcing)Time frame: Throughout the study period (Day 1 through Day 211)
- Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Sourcing)Time frame: Throughout the study period (Day 1 through Day 241)
- Number of Participants With SAEs, AEs Leading to Withdrawal and AESIs in Study Phase II (Sourcing)Time frame: Throughout the study period (Day 1 through Day 361)
Locations
53 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Longmont, Colorado
GSK Investigational Site
Doral, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Meridian, Idaho
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Springfield, Missouri
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Fortitude Valley, Queensland, Australia
GSK Investigational Site
Taringa, Queensland, Australia
GSK Investigational Site
Tarragindi, Queensland, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Spearwood, Western Australia, Australia
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Linkebeek, Belgium
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
Salvador, Brazil
GSK Investigational Site
São José do Rio Preto, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Helsinki, Finland
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Bydgoszcz, Poland
GSK Investigational Site
Bydgoszcz, Poland
GSK Investigational Site
Elblag, Poland
GSK Investigational Site
Katowice, Poland
GSK Investigational Site
Katowice, Poland
GSK Investigational Site
Krakow, Poland
GSK Investigational Site
Krakow, Poland
GSK Investigational Site
Luboń, Poland
GSK Investigational Site
Siemianowice Śląskie, Poland
GSK Investigational Site
Tarnów, Poland
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.